藥明生物(02269.HK)成立離岸合資公司 從事疫苗CDMO業務
藥明生物(02269.HK)公布,於2019年5月24日,公司已成立離岸合資公司;同時於2019年8月29日,藥明生物投資及離岸合資公司(兩者均為公司全資附屬)與海利生物訂立股份轉讓協議,據此,藥明生物投資同意按名義對價轉讓其所持有的離岸合資公司全部已發行股本的30%(即轉讓股份)予海利生物。完成後,離岸合資公司將分別由藥明生物投資及海利生物擁有70%及30%股權(即與在岸合資公司的最終所有權架構相同);及離岸合資公司將繼續為公司的附屬公司。
離岸合資公司計劃將主要從事疫苗CDMO(合同定制研發生產組織)業務,建設集疫苗原液(DS)及製劑(DP)生產、質量控制(QC)實驗室於一體的綜合疫苗生產基地,並為全球市場生產及供應疫苗。為滿足未來資金需要,藥明生物投資與海利生物(作為股東)可按股權比例進一步向離岸合資公司注資,時間及金額由離岸合資公司釐定,上限分別為9,800萬美元及4,200萬美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.